Repligen's $1.5B buyout locks BLFS to deal terms, not its own news
Repligen agrees to buy BioLife for $1.5 billion Repligen will pay $31 a share — $11.25 cash plus Repligen stock — a 24% premium to BioLife's recent average price. That buyout price now acts like a magnet for the stock: it trades near the deal value, and shareholders get cash plus Repligen shares when it closes.
The acquisition is the single force now setting BLFS's price.
Q2 beat shows the underlying business was healthy BioLife earned $0.04 a share versus an expected small loss, with revenue of $28.5 million, up about 21% from a year earlier and above forecasts — its fourth straight beat. Strong results support the deal price and make the buyer's case easier.
Shows the company's own performance still matters as a backstop to the deal.
Law firm probes whether the sale price is fair Investor-rights firm Halper Sadeh is investigating whether BioLife's board got shareholders a fair deal in the Repligen sale. Such reviews are common and often lead nowhere, but they can delay closing or pressure the buyer to raise its offer.
A real counterweight that could change deal terms or timing.
Removed from the S&P SmallCap 600 index BioLife is being dropped from the S&P SmallCap 600 and replaced by Freshworks, because it is being acquired. Index funds that tracked it must sell, but with the buyout nearly done, this mostly reflects the deal closing rather than new weakness.
Explains the forced selling around the deal's completion.